Platelet degranulation at the site of vascular injury prevents bleeding and may affect the chronic vascular wound healing response. Transforming Growth Factor (TGF)-β1 is a major component of platelet α-granules known to accumulating in thrombi. It was our aim to determine the role of TGFβ1 released from activated platelets for neointima formation following arterial injury and thrombosis. Mice with plateletspecific deletion of TGFβ1 (Plt.TGFβ-KO) underwent carotid artery injury. Immunoassays confirmed the absence of active TGFβ1 in platelet releasates and plasma of Plt.TGFβ-KO mice. Whole blood analyses revealed similar haematological parameters, and tail cut assays excluded major bleeding defects. Platelet aggregation and the acute thrombotic response to injury in vivo did not differ between Plt.TGFβ-KO and Plt.TGFβ-WT mice. Morphometric analysis revealed that absence of TGFβ1 in platelets resulted in a significant reduction of neointima formation with lower neointima area, intima-to-media ratio, and lumen stenosis. On the other hand, the media area was enlarged in mice lacking TGFβ1 in platelets and contained increased amounts of proteases involved in latent TGFβ activation, including MMP2, MMP9 and thrombin. Significantly increased numbers of proliferating cells and cells expressing the mesenchymal markers plateletderived growth factor receptor-β or fibroblast-specific protein-1, and the macrophage antigen F4/80, were observed in the media of Plt.TGFβ-KO mice, whereas the medial smooth muscle-actin-immunopositive area and collagen content did not differ between genotypes. Our findings support an essential role for platelet-derived TGFβ1 for the vascular remodelling response to arterial injury, apparently independent from the role of platelets in thrombosis or haemostasis.
Introduction
Inhibition of platelet aggregation is an established strategy to prevent thrombosis following vascular injury by balloon angioplasty and stent implantation, i. e. percutaneous interventional treatment of atherosclerotic lesions in humans (1) . Importantly, platelet activation at the site of vascular injury does not only play a role in acute thrombus formation, but the release of growth factors and cytokines from their granules may also affect the chronic vascular wound healing response to injury (2, 3) . Today, in the era of second-generation drug-eluting stents, and despite advanced antiplatelet agents and strategies, restenosis continues to be responsible for clinically relevant long-term sequelae of endovascular treatment (4).
The multifunctional cytokine transforming growth factor beta (TGFβ) is a major component of platelet α-granules, from which it is released upon degranulation (5) . Previous studies have shown that platelet clots retain significant amounts of TGFβ1; from there it is slowly released during thrombus resolution and may act locally on wound healing processes (6) . TGFβ receptors are expressed on numerous cell types, including endothelial (7) and smooth muscle cells (8) , and by binding to its receptors TGFβ1 may control smooth muscle cell proliferation, myofibroblast transdifferentiation, extracellular matrix production and fibrosis (9) (10) (11) . Indeed, previous studies have shown that adenoviral TGFβ1 overexpression (12) or recombinant TGFβ1 administration (13) following experimental arterial injury promote extracellular matrix accumulation and intimal hyperplasia. On the other hand, anti-bodies against TGFβ1 have been shown to reduce extracellular matrix accumulation and to suppress intimal hyperplasia after rat carotid artery balloon inflation (14) . TGFβ1 antisense oligonucleotides (15) or ribozymes (16) also were demonstrated to inhibit the increase in TGFβ1 mRNA expression and to reduce neointima formation after rat carotid artery balloon injury. However, there are multiple other cellular sources of TGFβ1 in addition to platelets, and vascular injury has been shown to be associated with upregulated TGFβ1 expression in smooth muscle cells, among others (17, 18) . TGFβ1 receptors are also expressed on platelets (19) , but the contribution of TGFβ1 released from activated platelets to the acute and chronic response to arterial injury has not been directly examined so far. Moreover, recent studies indicate that ablation of TGFβ signalling in smooth muscle cells may be deleterious. In fact, knockdown of TGFβ type I, and to a lesser extent of type II receptors in smooth muscle cells was found to cause severe aortopathy with medial thickening, haemorrhage and aneurysmal degeneration (20) (21) (22) .
In the present study, we examined the importance of TGFβ1, expressed in and released from activated platelets, for thrombus formation, resolution and the chronic vascular remodelling response following carotid artery injury in mice.
Material and methods

Experimental animals
To generate mice with platelet-specific deletion of transforming growth factor beta 1 (TGFB1), mice with loxP-flanked (floxed, fl/ fl) TGFB1 alleles (Tgfb1tm2.1Doe/J; (23)) were crossed with mice expressing Cre recombinase under control of the megakaryocytespecific platelet factor 4 (Pf4) promoter (C57BL/ 6-Tg(Pf4-cre)Q3Rsko/J; (24) ). Genotyping was performed with genomic DNA isolated from ear punch biopsies using the following primer sequences: Pf4.Cre for: 5'-CCC ATA CAG CAC ACC TTT TG-3'; Pf4.Cre rev: 5'-TGC ACA GTC AGC AGG TT-3'; TGFB1 for: 5'-AAG ACC TGG GTT GGA AGT G-3'; TGFB1 rev: 5'-CTT CTC CGT TTC TCT GTC ACC CTA T-3' . A representative image of a genomic DNA PCR analysis is shown in Suppl. Figure IA (available online at www.thrombosis-online.com). All animal care and experimental procedures had been approved by the institutional Animal Research Committee and complied with national guidelines for the care and use of laboratory animals. Age-and sex-matched littermates were used throughout the study.
Whole blood analyses and plasma preparation
Blood was collected by cardiac puncture from mice anaesthetised by intraperitoneal injection of 2 % xylazine (Bayer; 6 mg/kg body weight) and 10 % ketamine hydrochloride (hameln pharma plus; 100 mg/kg body weight). Haematological parameters were determined in whole blood anticoagulated with acid citrate dextrose (ACD; 0.25 mg/ml sodium citrate, 0.2 mg/ml D-glucose and 0.14 mg/ml citric acid; pH 4.5) using an automated haematology analyser (KX21N; Sysmex). Plasma was obtained from ethylenediamine tetraacetic acid (EDTA)-anticoagulated blood after centrifugation at 3,000 rpm for 10 minutes (min) and stored at -80 °C.
Bone marrow isolation
Bone marrow was obtained from hindlimb long bones by flushing the tibia and femur with 1X PBS using a 26G x ½'' needle. The cell suspension was centrifuged at 1,500 rpm for 5 min at 4 °C and the pellet resuspended in 50 µl 1X PBS.
Quantification of active TGFβ1 levels
Active TGFβ1 levels in releasates from thrombin-activated murine platelets as well as in plasma or bone marrow homogenates of mice were determined using a commercial enzyme-linked immunoassay (R&D Systems). To activate latent TGFβ1, one volume was acidified with 0.2 volume of 1 N HCl and incubated for 10 min at room temperature (RT) followed by neutralisation with 0.2 volume of 1.2 N NaOH in 0.5 M HEPES buffer.
Tail vein bleeding time
Female mice (9 to 15 weeks-of-age) were lightly anaesthetised with 0.5-1.0 % isoflurane and immobilised using a mouse restrainer (Föhr Medical Instruments). A distal 2 mm tail tip amputation was performed with surgical scissors, and the tail immediately immersed in a 50 ml Falcon tube filled with normal saline prewarmed to 37 °C with the tail tip positioned below the body horizon. The time to the first and the last bleeding stop for at least 30 seconds within a 10 min-monitoring period was recorded.
Isolation of washed platelets and platelet aggregation
Murine platelets were isolated from ACD-anticoagulated blood, as described (25, 26) . Blood was transferred to round-bottom polystyrene tubes (Corning) and 0.2 U adenosine 5'-triphosphate diphosphohydrolase (apyrase; Sigma) per ml blood was added. Then, 833 µl pre-warmed Tyrode's buffer (1X Tyrode buffer, 0.1 M HEPES, 2 % BSA, 1 % dextrose, 0.1 M MgCl 2 ; pH 6.5) plus 167 µl ACD were added per ml blood and gently mixed. After centrifugation at 150 g for 10 min at RT, the platelet-rich supernatant was transferred to a fresh tube, 0.2 U apyrase/ml added and the mixture again centrifuged at 300 g for 6 min at RT. The platelet-rich pellet was resuspended in 1 ml pre-warmed Tyrode's buffer (pH 6.5) containing 0.2 U/ml apyrase, rested for 5 min at 37 °C and centrifuged at 800 g for 6 min at RT. The platelet pellet was dissolved in 200 µl pre-warmed Tyrode's buffer (pH 7.4) and rested for 15-20 min at 37 °C. The number of platelets was automatically counted (Sysmex) and adjusted to 2 ×10 8 per ml with pre-warmed Tyrode's buffer (pH 7.4). Immediately prior to further analysis, 2 mM CaCl 2 were added. For measuring platelet aggregation, light transmission aggregometry was performed (APACT 4 S Plus; DiaSys Greiner). In brief, 200 µl of a washed platelet suspension (2×10 8 platelets/ml) were filled into a cuvette and thrombin from bovine plasma (100 U/ml; Sigma) was added. Platelet aggregation was measured over 10 min at 37 °C. Results are expressed as % change vs unstimulated platelets.
Induction of arterial injury and thrombosis
Male mice (10 to 14 weeks-of-age) were anaesthetised with a mixture of 1.5 % isoflurane (Abbott) and 0.5 % oxygen (AIR LIQUIDE Medical) via an automated ventilation system (Hugo Sachs Elektronik). Thrombus formation at the common carotid artery was induced using 10 % ferric chloride (FeCl 3 ), as described (25, 27) . Carotid blood flow was monitored using a miniature ultrasound flow probe (0.5 VB; Transonic Systems) connected to a flow meter (model T106; Transonic Systems) and a computerised data acquisition program (WinDaq; DATAQ Instruments). Blood flow was recorded over a 35-min period following arterial injury. Arterial thrombus formation was quantified by determining the time to first and to last occlusion (defined as blood flow reduction to 0.0 ± 0.2 ml/min), the presence of recanalisations as well as the patency of the vessel at the end of the monitoring period.
Morphometric quantification of neointima formation
Three weeks after vascular injury, mice were deeply anaesthetised by 3 % isoflurane and killed by cardiac puncture and blood draw followed by perfusion with 4 % zinc formalin (Sigma) over the left ventricle. Then, the injured (left) and uninjured (right) carotid artery were harvested. After a 24-hour (h) fixation in 4 % zinc formalin, carotid arteries were transferred to 70 % ethanol and embedded in paraffin wax (Surgipath ® Paraplast; Leica). To facilitate morphometric quantification, serial 5 µm-thick cross sections were stained with Verhoeff 's Elastica stain (VES) alone or in combination with Masson's trichrome (MTC) stain to simultaneously visualise elastic fibers (black), collagen (blue) and muscle/fibrin (red). Images were acquired on an Olympus BX51 microscope. Morphometric analyses were performed using image analysis software (Image-Pro Plus, version 7.0; Media Cybernetics). Sirius red staining was used to localise interstitial collagens, photographed under polarised light and the birefringence area quantified. A mean of six sections was evaluated per mouse and the average for each animal calculated.
Immunohistochemical analysis
Immunohistochemistry was performed on 4 % zinc formalin-fixed paraffin sections. First, sections were deparaffinised and endogenous peroxidase quenched using 3 % H 2 O 2 (in methanol; Roth). For some antibodies (anti-CD31, anti-PCNA), sections were permeabilised using 0.05 % Triton-X100 (in PBS; Roth) for 10 min at 37 °C. Epitope retrieval was performed by heating sections for 10 min at 800 W in 0.01 M citrate buffer (pH 6.0) or in 10 mM Tris/1 mM EDTA (pH 9.0). To block unspecific antigen binding sites, tissue sections were treated with 10 % normal serum (in PBS; Abcam) for 30 min. Endothelial or smooth muscle cells were analysed using mouse monoclonal antibodies against PECAM-1 (CD31; dilution, 1:20; Dianova) or smooth muscle-α-actin (SMA; dilution, 1:500; Sigma). Proliferating cells were visualised using mouse monoclonal antibody against proliferating cell nuclear antigen (PCNA; dilution, 1:500; Santa Cruz Biotechnology). To identify mesenchymal cells, a rabbit polyclonal antibody against fibroblast specific protein-1 (FSP1; dilution, 1:500; Novus Biologicals) and a rabbit monoclonal antibody against platelet-derived growth factor receptor-beta (PDGFRβ; dilution, 1:100; Abcam) were used. A monoclonal antibody against F4/80 (dilution, 1:200; Abd Serotec) was employed to visualise macrophages. Other antibodies used include antibodies against BMP7 (dilution, 1:300; Abcam), MMP2 (dilution, 1:50; Abcam), MMP9 (dilution, 1:50; Santa Cruz Biotechnology), SDF1α (dilution, 1:20; Santa Cruz Biotechnology), TGFβ receptor I (TGFβRI or ALK5; dilution, 1:400; Abbiotec) and TGFβRII (dilution, 1:30; Thermo Scientific) as well as thrombin (dilution, 1:50 in 0.5 % milk powder, Abcam). All primary antibodies were incubated overnight at 4 °C. On the next day, secondary antibodies were incubated for 1 h followed by a 30-min incubation with avidin-biotin peroxidase link (Vector Laboratories) and the peroxidase substrates 3-amino-9-ethylcarbazole or 3,3'-diaminobenzidine (both Vector Laboratories) until colour development. Sections were counterstained with Gill`s haematoxylin (Sigma) and mounted with ImmuMount (ThermoScientific). Sections were photographed on an Olympus BX51 microscope and analysed using Image-Pro Plus. To quantify lesion re-endothelialisation or endothelial TGFβ receptor expression, the length of the CD31-, TGFβRI-or TGFβRII-positive endothelium was measured per lumen length covering the neointima. PCNA staining was quantified by counting the number of immunopositive cells per total cells within the neointima or media. All other stainings were quantified by expressing the immunopositive area per neointima or media area. 
Statistical analysis
Normal distribution was examined using the D' Agostino & Pearson omnibus normality test. Quantitative values are presented as mean ± standard error of the mean (SEM) or as median with interquartile range (IQR). For comparison of two groups and normal distribution, Student's t test was performed. If normal distribution was not present, nonparametric Mann-Whitney test was applied. If more than two groups were compared, 1-Way Analysis of Variance followed by Sidak's multiple comparisons test was performed, or Kruskal-Wallis test followed by Dunn's multiple comparisons test, if values were not normally distributed. Non-parametric values were compared using Chi test. All analyses were performed using GraphPad PRISM data analysis software (version 6.03; GraphPad Software Inc.).
Results
Generation of mice lacking TGFβ1 in platelets
Mice with platelet-specific deletion of TGFβ1 were generated by crossing mice expressing Cre recombinase under control of the megakaryocyte-specific Pf4 promoter with mice carrying floxed (fl/fl) TGFβ1 alleles. Quantification of TGFβ1 levels in releasates of thrombin-activated platelets (Suppl. Figure IB , available online at www.thrombosis-online.com) and in plasma (Suppl. Figure IC , available online at www.thrombosis-online.com) from Plt TGFβ-WT and Plt TGFβ-KO mice confirmed the efficacy of the gene deletion and platelets as a major source of TGFβ1 in plasma.
Absence of TGFβ1 in murine platelets does not alter platelet counts, bleeding times or platelet aggregation
Analysis of whole blood did not reveal differences in haematological parameters, including the mean platelet number and mean platelet volume (▶ Table 1 ). Examination of mice using the tail bleeding assay revealed similar times to the first (Suppl. Figure IIA , available online at www.thrombosis-online.com) and the last (Suppl. Figure IIB , available online at www.thrombosis-online. com) bleeding stop thus excluding major bleeding defects in mice with platelet-specific deletion of TGFβ1. Ex vivo stimulation of washed platelets isolated from Plt TGFβ-WT and Plt TGFβ-KO mice with thrombin revealed a similar aggregatory response (Suppl. Figure IIC , available online at www.thrombosis-online. com; n=3 independent experiments using platelets from pooled blood of n=5 mice per genotype per experiment).
Absence of TGFβ1 in murine platelets does not affect arterial thrombus formation
Arterial thrombosis at the common carotid artery was induced in n=17 Plt TGFβ-WT and n=17 Plt TGFβ-KO mice using 10 % ferric chloride. Blood flow monitoring over 35 min after injury revealed that the time to first (7.9 ± 0.5 vs 8. To determine whether the observed differences in neointima formation were the consequence of differences in thrombus resolution, additional mice (n=5 per genotype) were subjected to FeCl 3 injury and the extent of thrombotic occlusion examined histologically 6 days later. These analyses revealed a similar thrombus size (p=0.841; Suppl. Figure IVA , available online at www.thrombosisonline.com) and degree of thrombotic lumen occlusion (p=0.841; Suppl. Figure IVB , available online at www.thrombosis-online. com) in Plt.TGFβ-WT and Plt.TGFβ-KO mice. Moreover, no differences were detected with regard to the relative content of fibrinous material, as determined using MTC stain (p=0.944; Suppl. Figure IVC , available online at www.thrombosis-online.com; representative images are shown in Suppl. Figure IVD , available online at www.thrombosis-online.com). Mean active TGFβ1 levels in plasma of Plt.TGFβ-WT mice increased from 7.8 ± 3.6 ng/ml at baseline to 8.2 ± 3.3 ng/ml at 6 days and 18.1 ± 3.8 ng/ml at 3 weeks after injury (n=8 mice per time point; Suppl. Figure VA , available online at www.thrombosisonline.com). In Plt.TGFβ-KO mice, active TGFβ1 levels were undetectable in plasma at baseline and at 6 days after injury, while at 21 days TGFβ1 could be detected in plasma of 2 out of 8 mice (median, 0.0 [0.0-1.2 ng/ml]; P<0.001 vs Plt.TGFβ-WT mice at day 21 after injury; Suppl. Figure VA , available online at www. thrombosis-online.com).
Absence of TGFβ1 in murine platelets is associated with smaller and more stable lesions
To further examine the effects of platelet-derived TGFβ on cellular lesion composition, a series of (immuno)-histochemical analyses was performed (in n=6-10 mice per genotype). First, we examined whether and how the absence of TGFβ release from activated platelets after injury affects the expression of TGFβ receptors within 
Vascular lesions of mice with deletion of TGFβ1 in platelets exhibit medial SMC de-differentiation and inflammation
As described above, morphometric analysis revealed significantly greater media area in mice with platelet-specific TGFβ1 deletion. Although the relative SMA-immunopositive area (12.6 ± 2.1 vs 10.9 ± 1.6 % in Plt.TGFβ-WT mice; P=0.525; not shown) and amount of interstitial collagen (p=0.759; Suppl. Figure VIIIA Figure 7 E and F), whereas quantitative analyses of these markers in the neointima did not reveal significant differences (not shown). The relative collagen content in the adventitia of vascular lesions of Plt.TGFβ-KO mice was found to be significantly increased (p<0.01; Suppl. Figure VIIIB and VIIIC, available online at www.thrombosis-online.com). Overall, these findings suggest that absence of TGFβ1 in platelets is associated with reduced neointima size and lumen stenosis. However, it also results in significant changes in the vessel media and adventitia, including TGFβ receptor I and II upregulation, increased protease expression, SMC de-differentiation and inflammation. 
Discussion
Platelet activation at the site of vascular injury contributes to tissue repair via the release and local deposition of growth factors including TGFβ1, and TGFβ receptors are expressed on vascular cells involved in neointima formation. Clinical evidence strongly supports a role for platelet inhibition to prevent thrombotic complications of vascular interventions (1), and beneficial effects of TGFβ1 neutralisation with regard to neointima formation have been documented in experimental models of vascular injury (14) (15) (16) . However, and because vascular injury also upregulates TGFβ expression in the vessel wall, the relevant cellular source and thus the primary target of any potential anti-TGFβ therapy remains unclear. Moreover, recent evidence indicates that ablation of TGFβ signalling in smooth muscle cells results in severe arteriopathy with aneurysmal dilation (20) (21) (22) . In the present study, we show that absence of TGFβ1 in platelets resulted in improved lesion re-endothelialisation and reduced neointima formation after carotid artery injury induced by 10 % ferric chloride in mice. Of note, absence of TGFβ1 in platelets affected neither haematopoiesis nor haemostasis, and it also had no effect on platelet aggregation or arterial thrombus formation. However, it should be noted that this desirable effect on neointima reduction was accompanied by a (non-significant) trend towards increased outward remodelling as well as increased proliferation and de-differentiation of medial smooth muscle cells and media inflammation.
TGFβ1 is a widely distributed cytokine, but platelets have been shown to contain up to 100-fold more TGFβ than other cells or tissues (5). Moreover, large amounts of TGFβ1 accumulate within blood clots from where TGFβ1 is released during plasmin resolution and may interact with its receptors on vascular cells to modulate the wound healing response (6). Human platelets have been shown to express TGFβ receptors, and although stimulation with exogenous TGFβ1 itself did not induce platelet aggregation, it potentiated platelet aggregation in response to ADP (19) and other agonists (28) . Moreover, analysis of mice with global TGFβ1 deficiency (on the SCID background to reduce the associated inflammatory phenotype) revealed an inability to sustain platelet fibrinogen binding in the absence of TGFβ1 (29) . In the present study involving mice with platelet-specific deletion of TGFβ1, we observed no differences between both genotypes with regard to either ex vivo platelet aggregation in response to thrombin or to thrombosis following arterial injury. Similar results were obtained in a recent study examining the importance of platelet-derived TGFβ1 for cardiac fibrosis during hypertrophy (30) . TGFβ1 has been shown to inhibit megakaryopoiesis in vitro (31) , and global TGFβ1 deficiency was found to be associated with elevated peripheral blood platelet counts and a mild bleeding disorder (29) . In our study, whole blood cell analysis revealed no differences in platelet number or size, or in any other haematological parameter, and bleeding times did not significantly differ between genotypes.
Platelet activation at the site of injury plays an important role not only for the acute response to injury, but the release of their granule content may also affect chronic vascular remodelling processes, as among others demonstrated in mice after induction of partial thrombocytopenia (32) . Several experimental studies demonstrated that pharmacological interventions to inhibit platelet aggregation had beneficial effects on the development of neointimal hyperplasia. For example, inhibition of the platelet glycoprotein Ib-von Willebrand factor interaction reduced neointima formation after arterial injury in rabbits (33) . P2Y 12 receptors play a central role in amplifying platelet α-granule secretion, and a reduced neointima formation was observed in P2Y 12 -deficient bone marrow-transplanted mice compared to controls (34) . Similar findings were reported after treatment with the P2Y 12 antagonist ticagrelor (35) . Although these studies consistently demonstrate the importance of activated platelets for post-thrombotic remodelling processes, the platelet-derived factors mediating these effects are less clear. Platelets contain a plethora of different cytokines, growth factors and other mediators, and targeting platelet activation per se may not be specific enough to modulate the cellular processes which control the development of restenosis. Of note, protein levels of SDF1α, a platelet-derived chemokine recently shown to induce the expression of TGFβ on human platelets (36), were found not to differ in vascular lesions of Plt.TGFβ-WT and Plt.TGFβ-KO mice.
Local overexpression of active human TGFβ1 plasmids (12) or administration of recombinant TGFβ1 (13) promotes intimal hyperplasia following experimental arterial injury. However, TGFβ1 is expressed by a number of other cell types involved in wound repair in addition to being released from activated platelets. For example, previous studies have shown that arterial injury markedly increased TGFβ1 expression in restenotic lesions of humans and rats (17, 18) . TGFβ1 mRNA transcripts started to increase early after rat balloon catheter injury and remained high over 2 weeks, and TGFβ immunosignals were abundant in neointimal smooth muscle cells (17) . Increased expression of TGFβ1, but also of TGFβ2 mRNA was observed in neointimal endothelial cells (37) . The increased expression of TGFβ1 in cells of the vessel wall may contribute to the sustained high plasma TGFβ1 levels after injury observed in this study, including in some of the Plt.TGFβ-KO mice. In this regard, an increased expression of proteases involved in latent TGFβ activation, including MMP2, MMP9 and thrombin, was observed in the media of Plt.TGFβ-KO mice, which also may have affected the vascular remodelling response by enhancing extracellular matrix degradation, collagen turnover and SMC migration. Elevated expression of MMP2 and MMP9 following vascular injury has been reported earlier and could be localised to non-contractile SMCs and macrophages, respectively (38) . Underlining the role of platelet TGFβ1 during vascular remodelling processes, TGFβ levels on the surface of platelets from patients with coronary artery disease undergoing percutaneous coronary intervention were significantly elevated in patients with acute coronary syndrome compared to patients with stable disease and independently associated with death and/or myocardial infarction during 12-month follow-up (39) . Moreover, restenosis after stent implantation was found to develop more frequently in patients with a polymorphism in the TGFB1 gene (40) . Using mice with plateletspecific deletion of TGFβ1, we could now directly demonstrate the important contribution of TGFβ1 released from activated platelets to neointima formation.
Neointima formation is primarily controlled by the proliferation and migration of smooth muscle cells and the production of extracellular matrix proteins, and earlier in vitro studies revealed that TGFβ1 can both stimulate and inhibit smooth muscle cell proliferation (9, 41) . Rats with heterozygous TGFβ deletion were characterised by a reduced expression of SMC differentiation markers, both at baseline and after injury (42) . Similarly, patients with TGFBR2 mutations exhibit decreased expression of contractile proteins in smooth muscle cells and myofibroblasts outgrown from aortic explants (43) . However, the role of TGFβ signalling in smooth muscle cells in vivo remained unclear, among others due to the severe phenotype of TGFβ-deficient mice dominated by multifocal inflammation. Recently, postnatal deletion of TGFβ receptor II in aortic smooth muscle cells was shown to cause severe aortopathy with early medial thickening, haemorrhage, elastolysis, aberrant SMC gene expression and aneurysmal dilation (20) . Similarly, SMC-specific inducible deletion of TGFβ type I receptors in adult mice was found to result in rapid and severe aneurysmal degeneration, whereas TGFβ type II receptor deletion caused a milder aortic pathology and attenuated the phenotype caused by absence of TGFβ type I receptors (21) . An increased outward remodelling due to reduced perivascular expression of collagen type I and type III or fibronectin was observed after administration of recombinant soluble TGFβ receptor II to rats following balloon catheter injury at the carotid artery (37, 44) . Although we also observed medial thickening as well as a moderate, non-significant increase in total vessel area, our findings (including those in uninjured arteries) suggest that inhibition of platelet TGFβ1 release might be less detrimental on the vascular phenotype than direct inhibition of TGFβ signalling in smooth muscle cells by directly targeting its receptors. Of note, both type I and type II TGFβ receptors were found to be significantly upregulated in the media and also the neointima of mice with platelet-specific deletion of TGFβ.
In addition to increased medial cell proliferation and de-differentiation, we found that vascular lesions of mice lacking TGFβ1 in platelets contained increased numbers of F4/80-immunopositive macrophages. In this regard, TGFβ1-deficient mice exhibit a massive inflammatory phenotype acompanied by tissue necrosis, wasting and early death suggesting a role for TGFβ in immune cell proliferation and extravasation (45, 46) . Previous studies have shown that TGFβ controls the activation of macrophages (47) .
Lesion re-endothelialisation following injury plays an important role in the control of SMC proliferation and restenosis (48, 49) . TGFβ receptors are expressed on endothelial cells (7) , and TGFβ purified from human platelets was shown to inhibit endothelial regeneration (50) . Moreover, mice with global TGFβ deficiency exhibit defects in endothelial differentiation and vasculogenesis. In this study, we found that absence of TGFβ1 in platelets was associated with improved lesion re-endothelialisation, in line with the role for TGFβ1 as a negative regulator of endothelial cell proliferation (50, 51) . The improved restoration of endothelial integrity after vascular injury in the absence of platelet-derived
What is known about this topic?
• TGFβ1 and its receptors are upregulated in atherosclerotic and restenotic vascular lesions, and vascular injury is associated with TGFβ1 overexpression.
• TGFβ1 overexpression promotes intimal hyperplasia, and inhibition of TGFβ1 or TGFβ signalling prevents the development of restenotic lesions.
• Platelets are a major source of TGFβ1 and accumulate in blood clots.
What does this paper add?
• Absence of TGFβ1 released from activated platelets does not affect platelet aggregation and arterial thrombosis in response to carotid artery injury.
• Genetic deletion of TGFβ1 in platelets results in smaller and better re-endothelialised neointimal lesions with a higher density of SMA-positive cells.
• The reduced lumen narrowing in mice with platelet-specific TGFβ1 deletion was associated with a more pronounced outward remodelling and increased media thickening, myofibroblast accumulation and inflammation.
TGFβ1 may have played a role in the observed reduction of neointima formation, and earlier studies have shown that smooth muscle cells appear only in intima areas not covered by endothelium (48) . The mechanisms underlying the improved re-endothelialisation in the absence of TGFβ may include reduced inhibitory TGFβ signalling mediated by ALK5 (52, 53) , although TGFβ receptor I levels were not found to differ in endothelial cells lining vascular lesions of Plt.TGFβ-WT or -KO mice. Of note, we did not examine the expression of ALK1, an additional type I receptor, coexpressed with ALK5 on endothelial cells (54) .
In conclusion, our findings suggest that absence of TGFβ1 in platelets promotes endothelial regeneration and prevents neointima formation and lumen loss after injury without affecting platelet aggregation or arterial thrombosis. 
